# Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT00869999** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 26 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00869999
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869999, "Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00869999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*